The VARIZIG Clinical Compendium is a comprehensive guide with the latest information on VZV post-exposure prophylaxis (PEP) for exposed high-risk patients, including an overview of the disease, leading guidelines recommendations for varicella PEP, and essential information about VARIZIG®.
The varicella zoster post-exposure prophylaxis navigator includes a treatment algorithm for VZV PEP based on the leading guidelines from relevant American Associations.
The VARIZIG patient resource for pregnant women provides information on the potential risks of varicella exposure during pregnancy, along with guidance on appropriate actions to take, emphasizing the importance of consulting their healthcare provider.
VARIZIG® contains trace amounts of IgA. Individuals known to have anaphylactic or severe systemic (hypersensitivity)
VARIZIG® contains trace amounts of IgA. Individuals known to have anaphylactic or severe systemic (hypersensitivity) reactions to human immune globulin preparations should not receive VARIZIG®. IgA-deficient patients with antibodies against IgA and a history of hypersensitivity may have an anaphylactoid reaction. Thrombotic events may occur during or following treatment with immune globulin products.